Evidence map›Paper›PMID 42141478›Full record

ArticleJournal of pharmaceutical health care and sciences2026

Validity and reliability of a cognitive function assessment tool using psychomotor function tests in patients with alcohol use disorders - a pilot study.

Yuma Shimizu, Junichi Miyaura, Manako Hanya, Masahide Okuda, Hiroaki Mizutani, Hiroyuki Kamei

Abstract read
In one paragraph

Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuma ShimizuOffice of Clinical Pharmacy Practice and Health Care Management, Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tenpaku-ku, Nagoya city, Aichi, 468-8503, Japan.
Junichi MiyauraOffice of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan.
Manako HanyaOffice of Clinical Pharmacy Practice and Health Care Management, Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tenpaku-ku, Nagoya city, Aichi, 468-8503, Japan.
Masahide OkudaDepartment of Psychiatry, Yagoto Hospital, Nagoya, Aichi, Japan.
Hiroaki MizutaniDepartment of Psychiatry, Yagoto Hospital, Nagoya, Aichi, Japan.
Hiroyuki KameiOffice of Clinical Pharmacy Practice and Health Care Management, Graduate School of Pharmacy, Meijo University, 150 Yagotoyama, Tenpaku-ku, Nagoya city, Aichi, 468-8503, Japan. hkamei@meijo-u.ac.jp.

Funding

Japan Society for the Promotion of Science KAKENHI, Grant Number JP23K06243 (Japan)
6 · The paper itself

Abstract

backgroundEven after alcohol detoxification, 50-80% of patients with alcohol use disorder (AUD) exhibit cognitive impairments, which affect key domains of social functioning, such as employment, interpersonal relationships, and communication. Therefore, it is necessary to assess cognitive function in patients with AUD in routine practice. However, existing cognitive function assessments are difficult to apply in routine practice because they require a long time, are burdensome on patients, and are limited to evaluators with special training. The present study investigated the relationship between a simple and novel assessment, called Psychomotor Function Tests (PFT), and existing Neuropsychological Tests (NT) in patients with AUD.

methodsTwenty patients with AUD underwent a cognitive assessment using NT (Raven's Colored Progressive Matrices, Frontal Assessment Battery (FAB), and Clinical Assessment for Attention (CAT)) as well as tablet-based PFT, with each assessment being conducted twice: 1 week and 2 months after alcohol detoxification with benzodiazepines. Twenty healthy controls underwent the same assessment.

resultsPsychomotor function assessed by PFT was significantly worse in patients with AUD than in healthy controls (p < 0.05). At both assessment time points, PFT composite score correlated with the total FAB score (r = 0.500, 0.458) and CAT time required (r = -0.447, -0.496). The CRT, CTT-TT, CTT-PAT and RVIP demonstrated a degree of test-retest reliability (r = 0.816, 0.812, 0.797, 0.676).

conclusionsThe correlations observed between PFT and conventional NT suggest the utility of PFT for evaluating cognitive function in patients with AUD in clinical settings.

Indexed as

Alcohol use disorderCognitive functionCognitive function assessmentPsychomotor function test

Identifiers

PMID42141478
PMCPMC13348581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.